Hjem › Brystkreft › New York › Rochester
Kliniske studier for Brystkreft i Rochester, NY
15 studier for Brystkreft søker deltakere på steder i og rundt Rochester (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
RekruttererFase 2
- University of Rochester Medical Center, Rochester
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekrutterer
- University of Rochester (URMC), Rochester
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekruttererFase 2
- Wilmot Cancer Institute, Rochester
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RekruttererFase 3
- Rochester General Hospital Lipson Cancer Institute, Rochester
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekruttererFase 3
- University of Rochester Medical, Rochester
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
RekruttererFase 1
- Wilmot Cancer Institute, Rochester
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
RekruttererFase 2
- University of Rochester Medical Center, Rochester
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruttererFase 3
- Pluta Cancer Center, Rochester
- University of Rochester, Rochester
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RekruttererFase 1
- University of Rochester - Wilmot Cancer Institute, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- University of Rochester Wilmot Cancer Institute, Rochester
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekruttererFase 3
- Wilmot Cancer Institute Radiation Oncology at Greece, Rochester
- Highland Hospital, Rochester
- Pluta Cancer Center, Rochester
- og 3 flere
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Rekrutterer
- University of Rochester, Rochester
Access to Genetic Testing in Underserved Patients With Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Rochester, Rochester
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
RekruttererFase 2
- University of Rochester, Rochester
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RekruttererObservasjonsstudie
- University of Rochester - Pluta Cancer Center, Rochester
Brystkreft-studier i andre byer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Nashville, TN81 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Rochester
- Akut myelogen leukemi16 studier
- Lungekreft15 studier
- Kreft (alle typer)14 studier
- Fedme14 studier
- Overvekt13 studier
- Ikke-småcellet lungekreft13 studier
- Prostatakreft10 studier
- Metastatisk kreft8 studier
- Multipelt myelom8 studier
- Blærekreft7 studier
- Myotonisk dystrofi7 studier
- Pankreaskreft7 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.